The researchers suggested that Ashkenazi Jewish women as well as women of other ancestries might benefit from broader genetic screening for breast cancer risk.
The Korean molecular diagnostics startup is planning to launch the new offering in Europe, as well as China and other Southeast Asian countries.
Researchers shored up their age-specific breast and ovarian cancer risk estimates by following thousands of individuals with pathogenic BRCA1/2 mutations.
The first randomized study to show a PARP inhibitor benefits advanced breast cancer patients is also a sign of the expanding utility of BRCA testing in precision medicine.
The team used genome- or exome-wide analysis of participants with BRCA 1/2 mutations to come to its conclusions.
The firm will use machine learning and bioinformatics, and will generate new genomic data to help improve and personalize treatment of BRCA mutation carriers.
The analysis from Quest Diagnostic researchers compared the cost-effectiveness of a seven-gene panel test to BRCA1 and BRCA2 testing alone in improving life expectancy.
BeiGene will use Myriad's myChoice HRD and BRACAnalysis CDx in the development program for its investigational PARP inhibitor BGB-290.
Using a new mathematical model, researchers uncovered mutational signatures related to homologous recombination deficiency in up to one-fifth of breast cancers.
Strata will refer castration-resistant prostate cancer patients with BRCA and ATM mutations for potential enrollment in Clovis' Rubraca studies.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.